SSY GROUP (02005): Obtain drug production registration approval for compound electrolyte sodium acetate glucose injection (250ml and 500ml) and metoclopramide hydrochloride injection (2ml:10mg).

SSY GROUP (02005) announced that the group has obtained the drug production registration certificates for compound electrolyte sodium acetate glucose infusion (250ml and 500ml) and metoclopramide hydrochloride injection (2ml:10mg) from the China National Medical Products Administration. They are all classified as chemical drugs class 3, equivalent to passing consistency evaluation. Compound electrolyte sodium acetate glucose infusion is mainly used to supplement and maintain water and electrolytes when oral administration is not possible or adequate intake is not possible, and to provide energy. Metoclopramide hydrochloride injection is an antiemetic drug, mainly used for (i) chemotherapy, radiotherapy, surgery, cranial injury, sequelae of brain injury, sea and air operations, and drug-induced vomiting; (ii) symptomatic treatment of nausea and vomiting symptoms of various diseases such as acute gastroenteritis, biliary pancreatic disease, uremic poisoning; (iii) used before diagnostic duodenal intubation (helps smooth intubation) and gastrointestinal barium X-ray examination (can reduce nausea, vomiting reactions, promote the passage of barium). The group's metoclopramide hydrochloride raw material has been approved and registered by the National Medical Products Administration as a raw material for marketed preparations.